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Matrix metalloproteinase-9 (MMP9) has been implicated in numerous somatic illnesses, including cardiovascular disorders and
cancer. Recently, MMP9 has been shown to be increasingly important in several aspects of central nervous system activity.
Furthermore, a pathogenic role for this enzyme has been suggested in such neuropsychiatric disorders as schizophrenia, bipolar
illness, and multiple sclerosis. In this paper, the results of biochemical and molecular-genetic studies on MMP9 that have been
performed in these pathological conditions will be summarized. Furthermore, I hypothesize that the MMP9 gene, as shown by
functional −1562 C/T polymorphism studies, may be mediating the relationship of neuropsychiatric illnesses (schizophrenia,
bipolar mood disorder, multiple sclerosis) that are comorbid with cardiovascular disease and cancer.
Copyright © 2009 Janusz K. Rybakowski. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1.Introduction
The matrix metalloproteinases (MMPs) are a large family
of zinc-dependent, extracellularly acting endopeptidases,
the substrates of which are proteins of the extracellular
matrix and adhesion proteins [1]. Matrix metalloproteinase-
9 (MMP9), also known as gelatinase B, 92kDa gelatinase, or
92Da type IV collagenase (which represents the largest and
most complex member of this family) has recently been a
subject of growing interest in human pathology.
In recent years, MMPs have attracted interest as media-
tors of both pathology and regeneration in the central ner-
vous system [2]. Concerning MMP9, a role for this enzyme
in the plasticity of the central nervous system has been
investigated in experimental studies [3]. Blocking of MMP9,
either by pharmacological or genetic means, selectively
inhibits hippocampal late-phase long-term potentiation as
well as fear memory in mice [4]. Furthermore, TIMP-
1, the endogenous inhibitor of MMP9, abolished MMP9-
dependent long-term potentiation in the prefrontal cortex
of freely moving rats [5]. In addition, a pathogenic role has
been proposed for MMP9 in an animal model of aberrant
plasticity [6] and temporal lobe epilepsy [7].
ThehumanMMP9genewasmappedtothechromosome
region 20q11.2–q13.1 [8] and several polymorphisms of
this gene were identiﬁed. The −1562 C/T polymorphism
(rs3918242) was shown to exert a functional eﬀect on
gene transcription. This single nucleotide polymorphism
(SNP) at −1562bp is due to a C to T substitution (−1562
C−→T), which results in the loss of binding of a nuclear
protein to this region and an increase in transcriptional
activity in macrophages. In these cells, the C/C geno-
type leads to a low promoter activity whereas the C/T
and T/T genotypes result in high transcriptional activity
[9].
The molecular-genetic studies of the functional
−1562C/T polymorphism of the MMP9 gene brought
about interesting results in cardiovascular, cancer, and
neuropsychiatric conditions. Research in cardiovascular
illness and cancer showed that carriers of the T allele have an
increased severity of coronary arteriosclerosis [10], increased
cardiac mortality [11], and increased risk or more severe
progression of some types of cancer [12, 13]. Recent studies
also demonstrated an association of this polymorphism with
a predisposition to schizophrenia [14], bipolar illness [15],
and multiple sclerosis [16, 17].2 Cardiovascular Psychiatry and Neurology
Based on the results of these studies, I hypothesize that
the MMP9 gene, which has a functional −1562C/T poly-
morphism, may mediate the epidemiological comorbidity
of neuropsychiatric illnesses (schizophrenia, bipolar mood
disorder, multiple sclerosis) with cardiovascular diseases and
cancer.
2.MMP-9inCardiovascularDisease
In a large prospective study of middle-aged men (465 cases,
1076 controls), Welsh et al. [18] showed an association
of serum MMP9 with the incidence of coronary heart
disease in the general population. More detailed studies
have recently been performed in middle-aged population by
Swedish researchers who found an association of circulating
MMP9 levels not only with cardiovascular [19] but also with
psychosocial risk factors for coronary artery disease (e.g.,
depression) [20]. Related to these observations, an inverse
relationship between markers of nitric oxide formation and
MMP9 was found in healthy subjects [21]. The higher
level of MMP9 in patients with coronary artery disease has
been recently reported [22]. Higher MMP9 level was also a
correlate of coronary artery ectasia [23] and a predictor of
increased mortality in patients with coronary artery disease
[24].
The association of MMP9 status with a progression of
coronary heart disease has also been conﬁrmed by molecular
genetic studies that used the functional −1562 C/T polymor-
phism of MMP9 gene. It was observed that the carriers of
the T allele had increased cardiac mortality [11], and more
recently, an association of T allele with myocardial infarction
in patients with coronary heart disease was found [25].
In cardiac patients, a relationship was also demonstrated
between the T allele of the −1562C/T polymorphism and
markedly increased levels of MMP9 [24], compatible with
higher transcriptional activity of this allele in experimental
studies [9]. A similar relationship between plasma MMP9
and the T allele of the −1562C/T polymorphism was also
shown in HIV patients under antiviral therapy [26].
Recently, Konstantino et al. [27] pointed out the promi-
nent role of MMP9 in plaque formation, destabilization,
and rupture, and postulated that MMP9 levels may serve as
a biomarker for acute coronary syndrome. An association
of MMP9 levels with atherosclerotic changes has been
previously found in patients with atherosclerosis of the
femoral artery [28] and with chronic periodontitis [29].
Higher levels of MMP9 were also observed in hypertrophic
cardiomyopathy, which correlated with a worse prognosis
[30]. In molecular-genetic studies that genotyped the func-
tional −1562 C/T polymorphism of the MMP9 gene, it was
observed that the carriers of the T allele had an increased
severity of coronary atherosclerosis [10].
The available data also show a possible association of
MMP9 with the pathogenesis and treatment of hypertensive
disease. Higher MMP9 level were found preclinically in
spontaneously hypertensive hyperlipidemic rats [31]a n d
clinically in women with gestational hypertension [32]. In
the group of 595 patients evaluated in the Framingham
Oﬀspring Study, higher MMP9 concentrations were related
to higher risk of blood pressure progression [33]. Recently,
it was demonstrated that plasma MMP9 samples were
inhibited by captopril to a similar extent as the angiotensin-
converting enzyme [34].
3. MMP-9 in Cancer
Sakata et al. [35] showed an overexpression of MMP9 in
an epithelial tumor of the ovary and its contribution to
lymph node metastases of ovarian carcinoma cells. Similarly,
in patients with breast cancer, increased serum and tissue
expression of MMP9 was associated with a worse prognosis
of the course of tumor [36]. Higher levels of MMP9 have
been reported in endometrial polyps, especially in those
occurring in premenopausal women [37]. Recently, higher
MMP9 levels were also observed in pulmonary lymphangio-
leiomyomatosis characterized by excessive cell proliferation
[38].
Molecular-genetic studies of the functional −1562 C/T
polymorphism of the MMP9 gene have revealed a frequent
association of T allele with an increased risk of some kinds of
cancerandwithmoresevereprogressionofthetumorand/or
greaterdynamicsofmetastases.Sugimotoetal.[12]observed
that the T allele was associated with endometrial carcinoma
risk in a Japanese population. Other studies showed an
association of the T allele with the risk for oral squamous cell
carcinoma in younger male areca users [39] and with genetic
risk for esophageal squamous cell carcinoma [40]. Kader
et al. [41] demonstrated that several MMP9 haplotypes
(including −1562 C/T polymorphism) were associated with
therisk ofinvasivecanceroftheurinarybladder.Concerning
gastric cancer, it has been found that the T allele of the
−1562 C/T polymorphism of MMP9 gene is associated with
an invasive phenotype of this tumor [42] and with a higher
frequency of lymph node metastasis [43]. In breast cancer,
Przybylowska et al. [44] reported that the T allele of this
polymorphism was associated with malignance and growth
o ft u m o r s ,a n dH u gh e seta l .[ 13] showed an association with
the severity of lymph node metastases. Higher risk of lymph
node metastases in colorectal cancer was also found to be
connected with the T allele [45].
4. MMP-9 inMultiple Sclerosis
AnupregulationofMMPswithadecreaseoftissueinhibitors
(TIMPs) in biological ﬂuids of multiple sclerosis (MS)
patients and in an animal model of the disease has been
found in numerous studies. Further, the potential of drugs
aﬀecting MMPs for treatment of MS has been discussed
[46]. A signiﬁcant elevation of MMP9 related to various
coursesofMShasbeenfound[47].Alsorecently,Shintoetal.
[48] demonstrated that omega-3 fatty acid supplementation
decreased MMP9 levels in relapsing-remitting MS.
In recent years, molecular-genetic studies have focused
on the functional −1562C/T polymorphism of the MMP9
gene in MS. In the ﬁrst study performed in Serbia, it was
found that T allele carriers had a lower susceptibility and
severity of MS, and the T allele was found signiﬁcantly
less frequently in women with MS [16]. The second studyCardiovascular Psychiatry and Neurology 3
performed in the Czech Republic conﬁrmed these ﬁndings,
showing a signiﬁcant decrease of T allele in patients with MS
compared to healthy subjects, especially females [17].
Recently, epidemiological studies investigating the
comorbidity of MS and vascular disease and cancer
were published. The ﬁrst study was performed on 9949
hospitalizations of MS patients in New York City from 1988
through 2002. It was found that MS patients were less likely
to be hospitalized for ischemic heart disease and myocardial
infarction. However, they were more likely to be hospitalized
for ischemic stroke than matched controls (general non-MS
population) [49]. A second study performed in Sweden
estimated cancer risk among 20276 patients with MS and
203951 individuals without MS using Swedish general
population register data. In patients with MS, there was a
decreased overall cancer risk, however, an increased risk for
brain tumors was observed [50].
5. MMP-9 inSchizophrenia
Studies on the MMP9 levels in schizophrenia have not yet
beenperformed.ToinvestigatetheMMP9geneinthisillness,
we genotyped the functional −1562C/T polymorphism in
a group of 442 schizophrenic patients and in 558 healthy
control subjects. Since MMP9 inﬂuences hippocampal and
prefrontal cortical activity [4, 5], we hypothesized that
ap o l y m o r p h i s mo ft h eMMP9 gene is associated with
the pathogenesis of schizophrenia, a condition in which
prefrontal cortex impairment is one of the most common
pathological ﬁndings [51]. A signiﬁcant preponderance of
the C/C genotype and C allele, and the diminished frequency
of the T allele of the −1562 polymorphism was found
in schizophrenia subjects compared to healthy controls
[14].
As shown previously, in both cardiovasular disease and
cancer, T allele carriers present more severe pathological
manifestations of these conditions [10–13]. Although the
risk of cardiovascular disease in schizophrenia is reported to
besimilartothatofthegeneralpopulation[52],somestudies
show a more benign course of cardiovascular illness in such
patients [53]. Also, compatible with our ﬁndings, a lower
predisposition to cancer in schizophrenic patients has long
been postulated [54], and the results of some recent analyses
may partially favor such a concept [55, 56].
6. MMP-9 in Bipolar Mood Disorder
Similar to schizophrenia, there are no studies measuring
MMP9 blood levels in patients with bipolar disorder. To
investigate the status of the MMP9 gene in this illness, we
genotyped the functional −1562C/T polymorphism in a
group of 416 patients with bipolar mood disorder, including
75 patients with bipolar type II, and in 558 healthy control
subjects. This approach has been substantiated by previous
reports on the signiﬁcance of MMP9 for hippocampal and
prefrontal cortical activity and for aspects of brain functions
such as neuroplasticity and epileptogenesis [4–7]. Patients
with bipolar mood disorder had a signiﬁcant preponderance
of T allele versus C allele of the −1562C/T polymorphism of
the MMP9 gene compared to healthy control subjects. The
higher frequency of the T allele was especially evident in a
subgroup of patients with bipolar disorder type II compared
to healthy subjects [15].
Compatible with the ﬁnding that T allele carriers present
more severe pathological manifestations of cardiovascular
disease and cancer [10–13] are ﬁndings from a recent
epidemiological study demonstraing an enhanced cancer
risk among patients with bipolar disorder [57]. A Swedish
epidemiological study also showed more than a 2.5-fold
increased mortality rate from cardiovascular disease in
bipolar patients [58].
7.MMP-9 andNeuropsychological Tests
In view of the experimental studies showing an involvement
of MMP9 in prefrontal cortex functions in rats [5], we also
performed neuropsychological tests measuring this activity
in patients with schizophrenia and bipolar illness, and in
control subjects in relation to −1562 C/T polymorphism of
MMP9 gene. 173 patients with schizophrenia (89 male, 84
female), mean age 29 years, 177 patients with bipolar illness
(68maleand109female),meanage43years,and181healthy
subjects (86 male and 95 female), mean age 35 years, were
included. For cognitive assessment, a computer version of
the Wisconsin Card Sorting Test (WCST) was employed,
with ﬁve domains reﬂecting working memory and executive
functions, depending primarily on prefrontal cortex activity.
Additionally, the Trail Making Test, A and B, and the Stroop
test, A and B, were used.
In schizophrenia patients, no diﬀerences were found
regarding neuropsychological performance among patients
with various genotypes of the polymorphism (data not
published). Among male patients with bipolar illness, the
results for C/C homozygotes (n = 50) were better on
all domains of the WCST compared with the remaining
genotypes (n = 18): no diﬀerences were found in female
patients.Bipolarmalesandfemalesdidnotdiﬀerinmeanage
(43+ 15years and 44+ 14years) or mean duration of illness
(12 + 12years and 14 + 11years, resp.). In males, the mean
age and mean duration of the illness of C/C homozygotes
were similar to patients with the remaining genotypes
[59].
In the only previous study measuring the impact of
MMP9 gene on cognitive functions, Vassos et al. [60]f o u n d
no association between hippocampus-dependent episodic
memory and functional repeat polymorphism (CA)n of the
MMP9 gene in healthy subjects. Also, in control subjects
studied by us, comparison of cognitive test results within
genotypes did not reveal signiﬁcant diﬀerences either in
the whole group or in male and female patients. The only
diﬀerence was in Stroop test, part A, in male patients,
where the results for C/C homozygotes (n = 66) were
better than other genotypes combined (n = 20). This
diﬀerence in performance related to genotypes was sim-
ilar to that obtained in male bipolar patients on WCST
domains. Healthy male and female subjects did not diﬀer
in mean age (34 ± 11years and 36 ± 12years, resp.)
[61].4 Cardiovascular Psychiatry and Neurology
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Figure 1: Epidemiological relationships between cardiovascular disorder, cancer, schizophrenia, multiple sclerosis, and bipolar mood
disorder and the functional −1562 polymorphism of the MMP9 gene.
Theseresultssuggestthatinhumans,neuropsychological
functions and MMP9 enzyme activity may not have a direct
correlation.Thus,increasedactivityoftheMMP9systemwas
associated with higher levels of prefrontal function in exper-
imental animals models [4, 5], also with neuropsychiatric
illnesses such as schizophrenia or multiple sclerosis [16, 17]
and The results obtained in males with bipolar illness on the
WCST and in healthy males on the Stroop test may suggest
that under certain conditions, a correlation of higher levels
of neuropsychological function with C allele (connected






Because of the functional implications of the −1562 C/T
polymorphism of the MMP9 gene, the comorbidity of
cardiovascular disorders, cancer, and such neuropsychiatric
illnesses as schizophrenia, bipolar mood disorder, and multi-
ple sclerosis can be hypothesized (Figure 1).
Hence,theTalleleofthe −1562polymorphismofMMP9
gene is related to a higher transcriptional activity of the




heart disease (CHD) [25] increased atherosclerosis [10], and
increased progression of hypertension [33]. Interestingly,
in neuropsychiatric disorders with a lower frequency of
the T allele, some epidemiological studies suggest a more
benign course of cardiovascular disease, for example, in
schizophrenia [53], and fewer cardiovascular hospitaliza-
tions in MS [49]. On the other hand, the phenomenon of
higher risk for cardiovascular illness and higher mortality
in patients with mood disorders (which have a higher
frequency of the T allel carriers) has long been observed
[58]. The proposed mediating factors include impairment in
endothelial function that was demonstrated both in bipolar
and unipolar depression [62] and, as hypothesized here,
possibility the MMP9 system.
In oncology, the carrying of the T allele of the −1562 C/T
MMP9 gene polymorphism is related to an increased risk
for some kinds of cancer [12], more severe progression of
tumor growth [42], and higher dynamics of metastases [45].
In neuropsychiatric disorders, some epidemiological studies
suggest a lower overall incidence of cancer in schizophrenia
[56] and in MS [50] (both illnesses with a lower frequency of
T allele carriers), and increased cancer morbidity in bipolar
mood disorder [57]. Interestingly, an association between
bipolar mood disorder and cancer has been also found with
respect to the levels of another metalloprotease, ADAM12 (a
disintegrin and metalloprotease) [63, 64].
Nevertheless, it should be emphasized that in the central
nervous system, there is more complex regulation of MMPs.
As Agrawal et al. [65] pointed out “the good guys may go
bad” under some conditions. There are several limitations
to this hypothesis. The majority of referred molecular
genetic research was performed with −1562 C/T functional
polymorphismsofMMP9buttheotherpolymorphismshave
not been suﬃciently studied. Literature data on the human
blood levels of MMPs used to develop this hypothesis were
not evaluated for possible methodological issues [66]. Also,
it should be acknowledged that there is a complex interplay
of the MMP9 gene with the other genes and environmental
factors of MMPs family and with a host of other genes
and with factors. However, it is conceivable that the MMP9Cardiovascular Psychiatry and Neurology 5
gene is a mediating factor among cardiovascular disorders,
cancer, schizophrenia, bipolar mood disorder, and multiple
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